

**Safety Data Sheet****Section 1: Identification****Product identifier**

- Product Name** • **Levobunolol Hydrochloride Ophthalmic Solution, 0.5%**
- Product Code** • AB28509; AB28511; Core No. 285; NDC 24208-0505-05; NDC 24208-0505-10; NDC 24208-0505-15

**Relevant identified uses of the substance or mixture and uses advised against**

- Recommended use** • Finished Pharmaceutical Product; Levobunolol Hydrochloride Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension.
- Restrictions on use** • Refer to the product insert and/or prescribing information for restrictions on use and contraindications.

**Details of the supplier of the safety data sheet**

- Manufacturer** • Bausch & Lomb  
1400 North Goodman Street  
Rochester, NY 14609  
United States  
bausch.com
- Telephone (General)** • 1-800-553-5340

**Emergency telephone number**

- Manufacturer** • 1-800-535-5053 - Infotrac

*This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to consumer use of the product.*

**Section 2: Hazard Identification****UN GHS**

According to: UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

**Classification of the substance or mixture**

- UN GHS** • Eye Mild Irritation 2B  
Specific Target Organ Toxicity Single Exposure 1

**Label elements**

**UN GHS**

**DANGER**



**Hazard statements** • May cause eye irritation

May cause damage to organs - Lungs, Heart  
Suspected of damaging fertility or the unborn child.

## Precautionary statements

**Prevention** ● Do not handle until all safety precautions have been read and understood.  
Wash thoroughly after handling.  
Use personal protective equipment as required.

**Response** ● IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
If eye irritation persists: Get medical advice/attention.  
IF ON SKIN: Wash with plenty of soap and water.  
If skin irritation or rash occurs: Get medical advice/attention.  
Specific treatment, see supplemental first aid information.

**Storage/Disposal** ● Keep tightly closed. Store at room temperature 15-25°C (59-77°F), to maintain product integrity. Use before date marked on carton and/or container.  
Dispose of content and/or container in accordance with local, regional, national, and/or international regulations.

## Other hazards

UN GHS

- No data available

## Section 3 - Composition/Information on Ingredients

### Substances

- Material does not meet the criteria of a substance according to United Nations Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

### Mixtures

Composition			
Chemical Name	Identifiers	%	Classifications According to Regulation/Directive
Benzalkonium Chloride, Solution, 10%	CAS:139-07-1 EINECS:205-351-5	0.004%	UN GHS: NDA
Edetate Disodium Dihydrate	CAS:139-33-3 EINECS:205-358-3	< 1%	UN GHS: NDA
Levobunolol HCl	CAS:27912-14-7 EINECS:248-725-3	0.5%	UN GHS: NDA
Polyvinyl Alcohol (540S)	CAS:9002-89-5	1.4%	UN GHS: NDA
Potassium Phosphate Monobasic	CAS:7778-77-0 EINECS:231-913-4	< 0.1%	UN GHS: NDA
Sodium chloride	CAS:7647-14-5 EINECS:231-598-3	< 1%	UN GHS: Skin Irrit. 2; Eye Irrit. 2A; Acute Tox. Oral 5
Sodium Metabisulfite	CAS:7681-57-4 EINECS:231-673-0	0.1%	UN GHS: Skin Irrit. 2; Eye Dam. 1; Eye Irrit. 2A; Acute Tox. Oral 4
Sodium Phosphate, Dibasic	CAS:7558-79-4 EINECS:231-448-7	< 1%	UN GHS: Skin Irrit. 2; Eye Irrit. 2A
Water	CAS:7732-18-5 EINECS:231-791-2	Balance	UN GHS: Classification criteria not met

Hydrochloric Acid (CAS:7647-01-0, EINECS:231-595-7) may be added to adjust the pH.

*The exact percentage of composition has been withheld as a trade secret.*

## Section 4: First-Aid Measures

### Description of first aid measures

- Inhalation**
  - No inhalation exposure expected with this formulation under normal conditions of use. If signs/symptoms develop, get medical attention.
- Skin**
  - Flush with fresh water if contact with skin or eyes. If skin irritation occurs: Get medical advice/attention.
- Eye**
  - For accidental and non-therapeutic applications, flush eyes with copious amounts of water for at least 15 minutes. Get medical attention. If eye irritation persists: Get medical advice/attention.
- Ingestion**
  - If accidentally ingested, efforts to decrease further absorption may be appropriate (gastric lavage). Call a physician or poison control center.

### Most important symptoms and effects, both acute and delayed

- As with other topically administered ophthalmic drugs, levobunolol may be absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. Severe respiratory and cardiac reactions, including death due to bronchospasm in patients with asthma, and death in association with cardiac failure have been reported with topical application of beta-adrenergic blocking agents.

### Indication of any immediate medical attention and special treatment needed

- Notes to Physician**
  - The most common signs and symptoms to be expected with overdosage with administration of a systemic beta-adrenergic blocking agent are symptomatic bradycardia, hypotension, bronchospasm, and acute cardiac failure. Should these symptoms occur, discontinue levobunolol therapy and initiate appropriate supportive therapy. The following supportive measures should be considered: 1. Symptomatic bradycardia: Use atropine sulfate intravenously in a dosage of 0.25 mg to 2 mg to induce vagal blockade. If bradycardia persists, intravenous isoproterenol hydrochloride should be administered cautiously. In refractory cases the use of a transvenous cardiac pacemaker should be considered. 2. Hypotension: Use sympathomimetic pressor drug therapy, such as dopamine, dobutamine or levarterenol. In refractory cases, the use of glucagon hydrochloride may be useful. 3. Bronchospasm: Use isoproterenol hydrochloride. Additional therapy with aminophylline may be considered. 4. Acute cardiac failure: Conventional therapy with digitalis, diuretics and oxygen should be instituted immediately. In refractory cases the use of intravenous aminophylline is suggested. This may be followed, if necessary, by glucagon hydrochloride which may be useful. 5. Heart block (second or third degree): Use isoproterenol hydrochloride or a transvenous cardiac pacemaker.

### Other information

- Have the product container or label with you when calling a poison control center or doctor, or going for treatment.

## Section 5: Fire-Fighting Measures

### Extinguishing media

- Suitable Extinguishing Media**
  - SMALL FIRES: Dry chemical, CO<sub>2</sub>, water spray or regular foam.
  - LARGE FIRE: Water spray, fog or regular foam.
- Unsuitable Extinguishing Media**
  - No data available

### Special hazards arising from the substance or mixture

- Unusual Fire and Explosion Hazards**
  - None known.
- Hazardous Combustion Products**
  - None known.

### Advice for firefighters

- Structural firefighters' protective clothing will only provide limited protection. Wear positive pressure self-contained breathing apparatus (SCBA).

## Section 6 - Accidental Release Measures

### Personal precautions, protective equipment and emergency procedures

#### Personal Precautions

- Wear suitable protective eyewear, clothing, respiratory protection, rubber boots and rubber gloves. Evacuate immediate area. Ensure adequate ventilation. Refer to Section 8.

#### Emergency Procedures

- Keep unauthorized personnel away. Ventilate closed spaces before entering. Stop leak if you can do it without risk.

### Environmental precautions

- Prevent spilled material from entering storm sewers or drains, waterways, and contact with soil.

### Methods and material for containment and cleaning up

#### Containment/Clean-up Measures

- Contain spilled product. For small spills, add suitable absorbent material. Scoop up and place in an appropriate liquid-tight container equipped with a tight cover for disposal. For large spills, dike spilled material or otherwise contain material to ensure runoff does not reach a waterway. Place spilled material in an appropriate, liquid-tight container equipped with a tight cover for disposal. Dispose of in accordance with Section 13.

## Section 7 - Handling and Storage

### Precautions for safe handling

#### Handling

- Avoid contact with product and use caution to prevent puncturing containers. No special protective equipment or procedures are required in the clinical or home environment.

### Conditions for safe storage, including any incompatibilities

#### Storage

- Keep tightly closed. Store at room temperature 15-25°C (59-77°F), to maintain product integrity. Use before date marked on carton and/or container. Protect from light.

#### Incompatible Materials or Ignition Sources

- None specified.

## Section 8 - Exposure Controls/Personal Protection

### Control parameters

#### Exposure Limits/Guidelines

- Refer to the occupational exposure limits / guidelines for the individual product components.

Exposure Limits/Guidelines				
	Result	ACGIH	Canada Quebec	NIOSH
Sodium Metabisulfite (7681-57-4)	TWAs	5 mg/m3 TWA	5 mg/m3 TWAEV	5 mg/m3 TWA

### Exposure Control Notations

#### ACGIH

- Sodium Metabisulfite (7681-57-4): **Carcinogens:** (A4 - Not Classifiable as a Human Carcinogen)

### Exposure controls

#### Engineering Measures/Controls

- Good general ventilation should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits.

If exposure limits have not been established, maintain airborne levels to an acceptable level.

### Personal Protective Equipment

#### Respiratory

- In the event of a bulk spill, and where risk assessment shows that air-purifying respirators are appropriate, a NIOSH (US) or CEN (EU) -certified air-purifying respirator equipped with HEPA cartridges may be permissible under certain circumstances where airborne concentrations are expected to exceed exposure limits, when adequate oxygen is present and as a backup to engineering controls. Use a positive pressure air-supplied respirator if there is any potential for an uncontrolled release or any other circumstances where air purifying respirators may not provide adequate protection.

#### Eye/Face

- Wear protective eyewear (goggles, face shield, or safety glasses) when handling bulk product before closed in final packaging. In the event of a spill, appropriate eye protection should be worn.

#### Hands

- Wear appropriate gloves.

#### Skin/Body

- No special personal protection required under conditions of intended use. In the event of a bulk spill, wear appropriate protective clothing.

### General Industrial Hygiene Considerations

- Wash thoroughly after handling.

### Environmental Exposure Controls

- No data available

## Section 9 - Physical and Chemical Properties

### Information on Physical and Chemical Properties

Material Description			
Physical Form	Liquid	Color	Clear Colorless to slightly yellow.
Odor	No odor.	Odor Threshold	Not relevant
General Properties			
Boiling Point	No data available	Melting Point	Not relevant
Decomposition Temperature	No data available	pH	5.5 to 7.5
Specific Gravity/Relative Density	= 1.018 Water=1	Water Solubility	Miscible
Viscosity	Not relevant		
Volatility			
Vapor Pressure	Not relevant	Vapor Density	Not relevant
Evaporation Rate	No data available		
Flammability			
Flash Point	Not relevant	UEL	Not relevant
LEL	Not relevant	Autoignition	Not relevant
Environmental			
Octanol/Water Partition coefficient	No data available		

## Section 10: Stability and Reactivity

### Reactivity

- No dangerous reaction known under conditions of normal use.

### Chemical stability

- Stable under normal temperatures and pressures.

### Possibility of hazardous reactions

- No data available

## Conditions to avoid

- Extreme heat or cold. Do not freeze.

## Incompatible materials

- No data available

## Hazardous decomposition products

- No data available

## Section 11 - Toxicological Information

### Information on toxicological effects

Components		
Levobunolol HCl (0.5%)	27912-14-7	<b>Acute Toxicity:</b> Eye-Man TDLo • 8571 nL/kg 9 Week(s)-Intermittent; <i>Behavioral:General anesthetic; Behavioral:Hallucinations, distorted perceptions; Cardiac:Pulse rate</i> ; Eye-Woman TDLo • 1 µL/kg 12 Hour(s)-Intermittent; <i>Lungs, Thorax, or Respiration:Respiratory obstruction</i> ; Ingestion/Oral-Rat LD50 • 700 mg/kg; <b>Tumorigen / Carcinogen:</b> Ingestion/Oral-Mouse TDLo • 112 g/kg 80 Week(s)-Continuous; <i>Tumorigenic:Neoplastic by RTECS criteria; Reproductive Effects:Tumorigenic Effects:Uterine tumors; Tumorigenic:Tumors after systemic administration not seen spontaneously</i>
Polyvinyl Alcohol (540S) (1.4%)	9002-89-5	<b>Acute Toxicity:</b> Ingestion/Oral-Rat LD50 • >20 g/kg; <i>Behavioral:Altered sleep time (including change in righting reflex); Behavioral:Somnolence (general depressed activity); Behavioral:Muscle weakness</i>
Benzalkonium Chloride, Solution, 10% (0.004%)	139-07-1	<b>Acute Toxicity:</b> Ingestion/Oral-Rat LD50 • 400 mg/kg
Edetate Disodium Dihydrate (< 1%)	139-33-3	<b>Acute Toxicity:</b> Ingestion/Oral-Rat LD50 • 2 g/kg
Sodium Metabisulfite (0.1%)	7681-57-4	<b>Acute Toxicity:</b> Ingestion/Oral-Rat LD50 • 1131 mg/kg; <i>Behavioral:Food intake (animal); Behavioral:Muscle weakness; Skin and Appendages:Other:Hair</i>
Sodium Phosphate, Dibasic (< 1%)	7558-79-4	<b>Acute Toxicity:</b> Ingestion/Oral-Rat LD50 • 17000 mg/kg
Potassium Phosphate Monobasic (< 0.1%)	7778-77-0	<b>Acute Toxicity:</b> Ingestion/Oral-Rat LDLo • 4640 mg/kg; <i>Behavioral:Somnolence (general depressed activity); Gastrointestinal:Other changes</i>
Sodium chloride (< 1%)	7647-14-5	<b>Acute Toxicity:</b> Ingestion/Oral-Rat LD50 • 3000 mg/kg

GHS Properties	Classification
<b>Acute toxicity</b>	UN GHS • Classification criteria not met
<b>Aspiration Hazard</b>	UN GHS • Classification criteria not met
<b>Carcinogenicity</b>	UN GHS • Classification criteria not met
<b>Germ Cell Mutagenicity</b>	UN GHS • Classification criteria not met
<b>Skin corrosion/Irritation</b>	UN GHS • Classification criteria not met
<b>Skin sensitization</b>	UN GHS • Classification criteria not met; Classification criteria not met
<b>STOT-RE</b>	UN GHS • Classification criteria not met
<b>STOT-SE</b>	UN GHS • Specific Target Organ Toxicity Single Exposure 1
<b>Toxicity for Reproduction</b>	UN GHS • Classification criteria not met
<b>Respiratory sensitization</b>	UN GHS • Classification criteria not met; Classification criteria not met

**Serious eye damage/Irritation**

UN GHS • Eye Mild Irritation 2B

**Target Organs**

- Lungs, Heart

**Potential Health Effects****Inhalation****Acute (Immediate)**

- May cause systemic effects.(See Eye).

**Chronic (Delayed)**

- No data available.

**Skin****Acute (Immediate)**

- Not expected to cause skin irritation.

**Chronic (Delayed)**

- Systemic absorption is possible with repeated or prolonged contact.(See Eye).

**Eye****Acute (Immediate)**

- Transient ocular burning and stinging. As with other topically applied ophthalmic drugs, levobunolol may be absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported with topical application of beta-adrenergic blocking agents.

**Chronic (Delayed)**

- Refer to the product insert and/or product prescribing information for comprehensive information regarding adverse reactions and other important symptoms and effects.

**Ingestion****Acute (Immediate)**

- Not expected to be an exposure route. However, may cause gastric and intestinal irritation if ingested. May cause systemic effects. (See Eye).

**Chronic (Delayed)**

- No data available.

Carcinogenic Effects			
	CAS	IARC	NTP
Sodium Metabisulfite	7681-57-4	Group 3-Not Classifiable	Not Listed
Polyvinyl Alcohol (540S)	9002-89-5	Group 3-Not Classifiable	Evidence of Carcinogenicity

**Reproductive Effects**

- Fetotoxicity (as evidenced by a greater number of resorption sites) has been observed in rabbits when doses of levobunolol hydrochloride equivalent to 200 and 700 times the recommended dose for the treatment of glaucoma were given. No fetotoxic effects have been observed in similar studies with rats at up to 1,800 times the human dose for glaucoma. Teratogenic studies with levobunolol in rats at doses up to 25 mg/kg/day (1,800 times the recommended human dose for glaucoma) showed no evidence of fetal malformations. There were no adverse effects on postnatal development of offspring. It appears when results from studies using rats and studies with other beta-adrenergic blockers are examined, that the rabbit may be a particularly sensitive species. There are no adequate and well-controlled studies in pregnant women.

**Other information**

- TARGET ORGAN: HEART/CARDIOVASCULAR: Bradycardia, arrhythmia, hypotension, syncope, heart block, cerebral vascular accident, cerebral ischemia, congestive heart failure, palpitation, cardiac arrest. TARGET ORGAN: LUNGS: Bronchospasm (predominantly in patients with pre-existing bronchospastic disease), respiratory failure, dyspnea, nasal congestion.

**Section 12 - Ecological Information****Toxicity**

- This material has not been tested for environmental effects.

**Persistence and degradability**

- No data available.

## Bioaccumulative potential

- No data available

## Mobility in Soil

- No data available

## Other adverse effects

## Section 13 - Disposal Considerations

### Waste treatment methods

#### Product waste

- Waste characterizations and compliance with applicable laws are the responsibility solely of the waste generator.

#### Packaging waste

- Dispose of content and/or container in accordance with local, regional, national, and/or international regulations.

## Section 14 - Transport Information

	UN number	UN proper shipping name	Transport hazard class (es)	Packing group	Environmental hazards
DOT	NDA	Not regulated	NDA	NDA	NDA
TDG	NDA	Not regulated	NDA	NDA	NDA
IMO/IMDG	NDA	Not regulated	NDA	NDA	NDA
IATA/ICAO	NDA	Not regulated	NDA	NDA	NDA

#### Special precautions for user

- No data available

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

- No data available

## Section 15 - Regulatory Information

### Safety, health and environmental regulations/legislation specific for the substance or mixture

#### SARA Hazard Classifications

- No data available

Inventory				
Component	CAS	Canada DSL	EU EINECS	TSCA
Levobunolol HCl	27912-14-7	Yes	Yes	No
Edetate Disodium Dihydrate	139-33-3	Yes	Yes	Yes
Benzalkonium Chloride, Solution, 10%	139-07-1	Yes	Yes	Yes
Potassium Phosphate Monobasic	7778-77-0	Yes	Yes	Yes
Polyvinyl Alcohol (540S)	9002-89-5	Yes	No	Yes



Sodium Metabisulfite	7681-57-4	Yes	Yes	Yes
Sodium chloride	7647-14-5	Yes	Yes	Yes
Sodium Phosphate, Dibasic	7558-79-4	Yes	Yes	Yes
Water	7732-18-5	Yes	Yes	Yes

## Canada

### Labor

#### Canada - WHMIS - Classifications of Substances

• Sodium Metabisulfite	7681-57-4	Uncontrolled product according to WHMIS classification criteria
• Edetate Disodium Dihydrate	139-33-3	Uncontrolled product according to WHMIS classification criteria (including 3.5%)
• Sodium Phosphate, Dibasic	7558-79-4	Not Listed
• Potassium Phosphate Monobasic	7778-77-0	Uncontrolled product according to WHMIS classification criteria
• Sodium chloride	7647-14-5	Uncontrolled product according to WHMIS classification criteria
• Benzalkonium Chloride, Solution, 10%	139-07-1	Not Listed
• Water	7732-18-5	Uncontrolled product according to WHMIS classification criteria
• Levobunolol HCl	27912-14-7	Not Listed
• Polyvinyl Alcohol (540S)	9002-89-5	Not Listed

#### Canada - WHMIS - Ingredient Disclosure List

• Sodium Metabisulfite	7681-57-4	1 %
• Edetate Disodium Dihydrate	139-33-3	Not Listed
• Sodium Phosphate, Dibasic	7558-79-4	Not Listed
• Potassium Phosphate Monobasic	7778-77-0	Not Listed
• Sodium chloride	7647-14-5	Not Listed
• Benzalkonium Chloride, Solution, 10%	139-07-1	Not Listed
• Water	7732-18-5	Not Listed
• Levobunolol HCl	27912-14-7	Not Listed
• Polyvinyl Alcohol (540S)	9002-89-5	Not Listed

## Europe

### Other

#### EU - CLP (1272/2008) - Annex VI - Table 3.2 - Classification

• Sodium Metabisulfite	7681-57-4	Xn; R22 R31 Xi; R41
• Edetate Disodium Dihydrate	139-33-3	Not Listed
• Sodium Phosphate, Dibasic	7558-79-4	Not Listed
• Potassium Phosphate Monobasic	7778-77-0	Not Listed
• Sodium chloride	7647-14-5	Not Listed
• Benzalkonium Chloride, Solution, 10%	139-07-1	Not Listed
• Water	7732-18-5	Not Listed
• Levobunolol HCl	27912-14-7	Not Listed
• Polyvinyl Alcohol (540S)	9002-89-5	Not Listed

**EU - CLP (1272/2008) - Annex VI - Table 3.2 - Labelling**

• Sodium Metabisulfite	7681-57-4	Xn R:22-31-41 S:(2)-26-39-46
• Edetate Disodium Dihydrate	139-33-3	Not Listed
• Sodium Phosphate, Dibasic	7558-79-4	Not Listed
• Potassium Phosphate Monobasic	7778-77-0	Not Listed
• Sodium chloride	7647-14-5	Not Listed
• Benzalkonium Chloride, Solution, 10%	139-07-1	Not Listed
• Water	7732-18-5	Not Listed
• Levobunolol HCl	27912-14-7	Not Listed
• Polyvinyl Alcohol (540S)	9002-89-5	Not Listed

**EU - CLP (1272/2008) - Annex VI - Table 3.2 - Safety Phrases**

• Sodium Metabisulfite	7681-57-4	S:(2)-26-39-46
• Edetate Disodium Dihydrate	139-33-3	Not Listed
• Sodium Phosphate, Dibasic	7558-79-4	Not Listed
• Potassium Phosphate Monobasic	7778-77-0	Not Listed
• Sodium chloride	7647-14-5	Not Listed
• Benzalkonium Chloride, Solution, 10%	139-07-1	Not Listed
• Water	7732-18-5	Not Listed
• Levobunolol HCl	27912-14-7	Not Listed
• Polyvinyl Alcohol (540S)	9002-89-5	Not Listed

**United States****Environment****U.S. - CERCLA/SARA - Hazardous Substances and their Reportable Quantities**

• Sodium Metabisulfite	7681-57-4	Not Listed
• Edetate Disodium Dihydrate	139-33-3	Not Listed
• Sodium Phosphate, Dibasic	7558-79-4	5000 lb final RQ; 2270 kg final RQ
• Potassium Phosphate Monobasic	7778-77-0	Not Listed
• Sodium chloride	7647-14-5	Not Listed
• Benzalkonium Chloride, Solution, 10%	139-07-1	Not Listed
• Water	7732-18-5	Not Listed
• Levobunolol HCl	27912-14-7	Not Listed
• Polyvinyl Alcohol (540S)	9002-89-5	Not Listed

**United States - California****Environment****U.S. - California - Proposition 65 - Carcinogens List**

• Sodium Metabisulfite	7681-57-4	Not Listed
• Edetate Disodium Dihydrate	139-33-3	Not Listed
• Sodium Phosphate, Dibasic	7558-79-4	Not Listed
• Potassium Phosphate Monobasic	7778-77-0	Not Listed
• Sodium chloride	7647-14-5	Not Listed
• Benzalkonium Chloride, Solution, 10%	139-07-1	Not Listed
• Water	7732-18-5	Not Listed
• Levobunolol HCl	27912-14-7	Not Listed
• Polyvinyl Alcohol (540S)	9002-89-5	Not Listed

**U.S. - California - Proposition 65 - Developmental Toxicity**

• Sodium Metabisulfite	7681-57-4	Not Listed
• Edetate Disodium Dihydrate	139-33-3	Not Listed

• Sodium Phosphate, Dibasic	7558-79-4	Not Listed
• Potassium Phosphate Monobasic	7778-77-0	Not Listed
• Sodium chloride	7647-14-5	Not Listed
• Benzalkonium Chloride, Solution, 10%	139-07-1	Not Listed
• Water	7732-18-5	Not Listed
• Levobunolol HCl	27912-14-7	Not Listed
• Polyvinyl Alcohol (540S)	9002-89-5	Not Listed

**U.S. - California - Proposition 65 - Reproductive Toxicity - Female**

• Sodium Metabisulfite	7681-57-4	Not Listed
• Edetate Disodium Dihydrate	139-33-3	Not Listed
• Sodium Phosphate, Dibasic	7558-79-4	Not Listed
• Potassium Phosphate Monobasic	7778-77-0	Not Listed
• Sodium chloride	7647-14-5	Not Listed
• Benzalkonium Chloride, Solution, 10%	139-07-1	Not Listed
• Water	7732-18-5	Not Listed
• Levobunolol HCl	27912-14-7	Not Listed
• Polyvinyl Alcohol (540S)	9002-89-5	Not Listed

**U.S. - California - Proposition 65 - Reproductive Toxicity - Male**

• Sodium Metabisulfite	7681-57-4	Not Listed
• Edetate Disodium Dihydrate	139-33-3	Not Listed
• Sodium Phosphate, Dibasic	7558-79-4	Not Listed
• Potassium Phosphate Monobasic	7778-77-0	Not Listed
• Sodium chloride	7647-14-5	Not Listed
• Benzalkonium Chloride, Solution, 10%	139-07-1	Not Listed
• Water	7732-18-5	Not Listed
• Levobunolol HCl	27912-14-7	Not Listed
• Polyvinyl Alcohol (540S)	9002-89-5	Not Listed

## Section 16 - Other Information

<b>Last Revision Date</b>	<ul style="list-style-type: none"> <li>19/May/2015</li> </ul>
<b>Preparation Date</b>	<ul style="list-style-type: none"> <li>19/May/2015</li> </ul>
<b>Disclaimer/Statement of Liability</b>	<ul style="list-style-type: none"> <li>To the best of our knowledge, the information contained herein is accurate. However, neither Bausch &amp; Lomb, Inc. nor any of its subsidiaries assumes any liability whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist. NO WARRANTY, EXPRESS OR IMPLIED, OF MERCHANTABILITY, FITNESS OR OTHERWISE IS MADE. In no event shall Bausch &amp; Lomb, Inc. or any of its subsidiaries be liable for any special, incidental or consequential damages.</li> </ul>